Finland· FI-REL-REL29023
Relistor
A methylnaltrexone bromide product containing methylnaltrexone bromide, registered in Finland by Bausch Health Ireland Limited. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Methylnaltrexone bromide is registered in 11 of 19 countries.
Countries holding a registration under ATC A06AH01 (methylnaltrexone bromide), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Methylnaltrexone bromide · ATC A06AH01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Methylnaltrexone bromide
- Manufacturer
- Bausch Health Ireland Limited
- Country
- Finland (FI)
- ATC code
- A06AH01
- ATC class
- Methylnaltrexone bromide
- Defined daily dose
- 6 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
13 interactions on record for methylnaltrexone bromide.
Graded by severity as the source publishes them — 13 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Methylnaltrexone bromide · interactions on record
13 records
- 13 moderate
Most severe, free to view
- AlvimopanA06AH02moderate
- NaloxegolA06AH03moderate
- NaloxoneA06AH04moderate
- NaldemedineA06AH05moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Methylnaltrexone bromide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRELISTORBausch Health Ireland Limited, Dublin
- United StatesRelistorSalix Pharmaceuticals, Inc.
- IrelandRelistorBausch Health Ireland Limited
- PolandRelistorBausch Health Ireland Ltd.
- SwedenRelistor 12 mg Injektionsvätska, lösning i förfylld sprutaBausch Health Ireland Ltd
- BelgiumRelistor 12 mgBausch Health Ireland
- SwitzerlandRelistor, InjektionslösungCuratis AG
- NorwayRelistorPharmaSwiss Ceska republika s.r.o.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Relistor
- Iceland · Relistor
- Liechtenstein · Relistor
- Norway · Relistor
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/42365bac-bde6-4b7e-9188-aeb1eaacc639 GET /v1/drugs/42365bac-bde6-4b7e-9188-aeb1eaacc639?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "6",
"form": "injektioneste, liuos",
"route": "Ihon alle",
"ddd_unit": "mg",
"strength": "12 mg / 0.6 ml",
"atc_label": "metyylinaltreksonibromidi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/08/463/001-003, 012-013",
"fimea_rel_id": "REL29023",
"authorised_at": "2008-07-02"
}See everything about methylnaltrexone bromide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.